GATA3 positivity in benign radiated prostate glands

Sara E. Wobker, Armen Khararjian, Jonathan Ira Epstein

Research output: Contribution to journalArticle

Abstract

Histologic changes following radiation therapy to the prostate include multilayering of glands, atrophy, squamous metaplasia, and often marked random nuclear atypia. We have seen multiple consultation cases where the differential diagnosis of these radiated prostate glands included urothelial carcinoma, with multilayered to solid-appearing proliferations that were positive by immunohistochemistry for GATA3. To formally investigate this issue, 30 cases of benign prostate tissue with radiation atypia, from 1990 to 2015, were obtained from our institution. Cases were evaluated by immunohistochemistry for the prostate-specific markers prostate-specific antigen (PSA), P501S (Prostein), and NKX3.1 and urothelial markers GATA3 and uroplakin 2. GATA3 was positive in 100% of cases, with 70% showing moderately strong to strong staining in a mostly patchy manner within a gland. PSA was positive in 93.3% of cases, with 89.2% showing moderately strong to strong staining in a mostly diffuse manner. P501S was positive in 96.7% of cases, with 93.1% showing moderately strong to strong staining in a mostly patchy manner. NKX3.1 was positive in 82.8% of cases, with 33.3% showing moderately strong to strong staining in a mostly patchy manner. Uroplakin 2 was negative in 100% of cases. Our findings highlight that GATA3 is often positive in benign prostate glands with radiation atypia, which along with the morphologic features present a pitfall for the misdiagnosis of urothelial carcinoma. A combination of PSA and P501S is the best prostate-specific panel for use in radiated prostate, with the caveat that they are often patchy and do not stain all radiated glands.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume41
Issue number4
DOIs
StatePublished - 2017

Fingerprint

Prostate
Uroplakin II
Prostate-Specific Antigen
Staining and Labeling
Immunohistochemistry
Radiation
Carcinoma
Differentiation Antigens
Metaplasia
Diagnostic Errors
Atrophy
Differential Diagnosis
Radiotherapy
Referral and Consultation

Keywords

  • benign
  • GATA3
  • immunohistochemistry
  • prostate
  • radiation

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

GATA3 positivity in benign radiated prostate glands. / Wobker, Sara E.; Khararjian, Armen; Epstein, Jonathan Ira.

In: American Journal of Surgical Pathology, Vol. 41, No. 4, 2017, p. 557-563.

Research output: Contribution to journalArticle

Wobker, Sara E. ; Khararjian, Armen ; Epstein, Jonathan Ira. / GATA3 positivity in benign radiated prostate glands. In: American Journal of Surgical Pathology. 2017 ; Vol. 41, No. 4. pp. 557-563.
@article{d4d6c671e894496ab6cf33296184ae15,
title = "GATA3 positivity in benign radiated prostate glands",
abstract = "Histologic changes following radiation therapy to the prostate include multilayering of glands, atrophy, squamous metaplasia, and often marked random nuclear atypia. We have seen multiple consultation cases where the differential diagnosis of these radiated prostate glands included urothelial carcinoma, with multilayered to solid-appearing proliferations that were positive by immunohistochemistry for GATA3. To formally investigate this issue, 30 cases of benign prostate tissue with radiation atypia, from 1990 to 2015, were obtained from our institution. Cases were evaluated by immunohistochemistry for the prostate-specific markers prostate-specific antigen (PSA), P501S (Prostein), and NKX3.1 and urothelial markers GATA3 and uroplakin 2. GATA3 was positive in 100{\%} of cases, with 70{\%} showing moderately strong to strong staining in a mostly patchy manner within a gland. PSA was positive in 93.3{\%} of cases, with 89.2{\%} showing moderately strong to strong staining in a mostly diffuse manner. P501S was positive in 96.7{\%} of cases, with 93.1{\%} showing moderately strong to strong staining in a mostly patchy manner. NKX3.1 was positive in 82.8{\%} of cases, with 33.3{\%} showing moderately strong to strong staining in a mostly patchy manner. Uroplakin 2 was negative in 100{\%} of cases. Our findings highlight that GATA3 is often positive in benign prostate glands with radiation atypia, which along with the morphologic features present a pitfall for the misdiagnosis of urothelial carcinoma. A combination of PSA and P501S is the best prostate-specific panel for use in radiated prostate, with the caveat that they are often patchy and do not stain all radiated glands.",
keywords = "benign, GATA3, immunohistochemistry, prostate, radiation",
author = "Wobker, {Sara E.} and Armen Khararjian and Epstein, {Jonathan Ira}",
year = "2017",
doi = "10.1097/PAS.0000000000000798",
language = "English (US)",
volume = "41",
pages = "557--563",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - GATA3 positivity in benign radiated prostate glands

AU - Wobker, Sara E.

AU - Khararjian, Armen

AU - Epstein, Jonathan Ira

PY - 2017

Y1 - 2017

N2 - Histologic changes following radiation therapy to the prostate include multilayering of glands, atrophy, squamous metaplasia, and often marked random nuclear atypia. We have seen multiple consultation cases where the differential diagnosis of these radiated prostate glands included urothelial carcinoma, with multilayered to solid-appearing proliferations that were positive by immunohistochemistry for GATA3. To formally investigate this issue, 30 cases of benign prostate tissue with radiation atypia, from 1990 to 2015, were obtained from our institution. Cases were evaluated by immunohistochemistry for the prostate-specific markers prostate-specific antigen (PSA), P501S (Prostein), and NKX3.1 and urothelial markers GATA3 and uroplakin 2. GATA3 was positive in 100% of cases, with 70% showing moderately strong to strong staining in a mostly patchy manner within a gland. PSA was positive in 93.3% of cases, with 89.2% showing moderately strong to strong staining in a mostly diffuse manner. P501S was positive in 96.7% of cases, with 93.1% showing moderately strong to strong staining in a mostly patchy manner. NKX3.1 was positive in 82.8% of cases, with 33.3% showing moderately strong to strong staining in a mostly patchy manner. Uroplakin 2 was negative in 100% of cases. Our findings highlight that GATA3 is often positive in benign prostate glands with radiation atypia, which along with the morphologic features present a pitfall for the misdiagnosis of urothelial carcinoma. A combination of PSA and P501S is the best prostate-specific panel for use in radiated prostate, with the caveat that they are often patchy and do not stain all radiated glands.

AB - Histologic changes following radiation therapy to the prostate include multilayering of glands, atrophy, squamous metaplasia, and often marked random nuclear atypia. We have seen multiple consultation cases where the differential diagnosis of these radiated prostate glands included urothelial carcinoma, with multilayered to solid-appearing proliferations that were positive by immunohistochemistry for GATA3. To formally investigate this issue, 30 cases of benign prostate tissue with radiation atypia, from 1990 to 2015, were obtained from our institution. Cases were evaluated by immunohistochemistry for the prostate-specific markers prostate-specific antigen (PSA), P501S (Prostein), and NKX3.1 and urothelial markers GATA3 and uroplakin 2. GATA3 was positive in 100% of cases, with 70% showing moderately strong to strong staining in a mostly patchy manner within a gland. PSA was positive in 93.3% of cases, with 89.2% showing moderately strong to strong staining in a mostly diffuse manner. P501S was positive in 96.7% of cases, with 93.1% showing moderately strong to strong staining in a mostly patchy manner. NKX3.1 was positive in 82.8% of cases, with 33.3% showing moderately strong to strong staining in a mostly patchy manner. Uroplakin 2 was negative in 100% of cases. Our findings highlight that GATA3 is often positive in benign prostate glands with radiation atypia, which along with the morphologic features present a pitfall for the misdiagnosis of urothelial carcinoma. A combination of PSA and P501S is the best prostate-specific panel for use in radiated prostate, with the caveat that they are often patchy and do not stain all radiated glands.

KW - benign

KW - GATA3

KW - immunohistochemistry

KW - prostate

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=85015213247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015213247&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000798

DO - 10.1097/PAS.0000000000000798

M3 - Article

C2 - 28291125

AN - SCOPUS:85015213247

VL - 41

SP - 557

EP - 563

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 4

ER -